SOUTH SAN FRANCISCO, Calif., Oct. 25, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, presented results from preclinical studies of three of the company's product candidates, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), Alocrest(tm) (vinorelbine tartrate injection, OPTISOME(tm)), and Brakiva(tm) (topotecan hydrochloride injection, OPTISOME(tm)) at the "Molecular Targets and Cancer Therapeutics" International Conference sponsored by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC).
